Shirish Kirtane, MD
Pulmonary Disease · Altamonte Springs, FLNPI 1982693115
Payments from drug & device makers
Across 441 payments — averaging $888.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$219K
- AstraZeneca$126K
- Mannkind Corporation$40K
- Regeneron$2K
- GSK$935
- Boehringer Ingelheim$874
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,22098%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 116 | $219,009 |
| AstraZeneca | 103 | $126,199 |
| Mannkind Corporation | 13 | $40,454 |
| Regeneron | 7 | $1,680 |
| GSK | 61 | $935 |
| Boehringer Ingelheim | 41 | $874 |
| Pfizer | 2 | $722 |
| Insmed, Inc. | 33 | $504 |
| Grifols USA, LLC | 20 | $383 |
| Bayer | 14 | $215 |
| Actelion Pharmaceuticals US, Inc. | 8 | $152 |
| Regeneron Healthcare Solutions, Inc. | 2 | $108 |
| Electromed, Inc. | 7 | $108 |
| Genentech USA, Inc. | 3 | $49 |
| Mylan Specialty L.p. | 1 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Viatris Specialty LLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 1 | $28 |
| United Therapeutics Corporation | 2 | $26 |
| Philips North America LLC | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$391,609 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 27 | $352,576 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 375 | $292,624 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 140 | $91,756 |
| SymbicortBudesonide/Formoterol Fumarate | 106 | $40,382 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $39,953 |
| Spiriva RespimatTiotropium Bromide | 42 | $39,854 |
| Ambrisentan | 11 | $31,350 |
| Advair HfaFluticasone Propion/Salmeterol | 77 | $31,233 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $16,837 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $16,734 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $16,187 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 490 | $14,685 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $6,500 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $4,922 |
| BreynaBudesonide/Formoterol Fumarate | 36 | $3,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $874 | $426,001120 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $935 | $351,996500 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $126,199 | $138,638257 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $12 | $53315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Altamonte Springs
- Francisco CalimanoAltamonte Springs$1.3M
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.